UPDATE: TransMedics Group (TMDX) Prices 5M Share Common Offering at $14/Sh
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/8/2026
- Wall St futures decline as oil surge, high yields stoke inflation worries
- Oil jumps as Middle East supply concerns persist amid shipping attacks
- Goldman Sachs sees 18% upside for Palantir on sovereign AI growth
- Citi names 5 top chip picks ahead of Q3 earnings
- PepsiCo shares climb after Q3 beat, though company trims profit forecast
- Anthropic launches Claude Haiku 5.5 with tiered pricing structure
- Sportradar to sell Synergy Sports coaching unit for $170M
- Rezolve AI (RZLV) Reiterated at Overweight by Cantor Fitzgerald on Positioning as Key Component in E-Commerce Stack
- Wall Street ends lower, off record highs, as Treasury yields climb
- Applied Digital (APLD) Tops Q1 EPS by 26c, Beats on Revenue
TransMedics Group (TMDX) Announces Proposed $60M Public Offering of Common Stock
May 26, 2020 7:14 AM EDTTransMedics Group, Inc. (TransMedics) (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart and liver failure, announced today the commencement of a proposed public offering of $60 million of its shares of common stock. All of the shares will be offered by TransMedics. TransMedics also expects to grant the underwriters a 30-day option to purchase... More
TransMedics Group (TMDX) Reports U.S. Pivotal OCS Liver PROTECT Trial Achieved Primary Clinical Objectives
May 26, 2020 7:10 AM EDTTransMedics Group, Inc. (NASDAQ: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart and liver failure, today reported positive top-line results from its U.S. Pivotal OCS Liver PROTECT Trial. The trial achieved its primary clinical objectives by meeting both the primary and secondary effectiveness and safety endpoints. For... More



